(NASDAQ: VRNA) Verona Pharma's forecast annual revenue growth rate of 84.39% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Verona Pharma's revenue in 2025 is $118,535,000.On average, 5 Wall Street analysts forecast VRNA's revenue for 2025 to be $199,034,536,093, with the lowest VRNA revenue forecast at $180,479,845,830, and the highest VRNA revenue forecast at $246,862,376,294. On average, 5 Wall Street analysts forecast VRNA's revenue for 2026 to be $388,248,244,349, with the lowest VRNA revenue forecast at $320,191,678,183, and the highest VRNA revenue forecast at $530,379,187,693.
In 2027, VRNA is forecast to generate $482,310,253,660 in revenue, with the lowest revenue forecast at $450,995,297,768 and the highest revenue forecast at $519,196,247,811.